Compare · PDD vs SLP
PDD vs SLP
Side-by-side comparison of PDD Holdings Inc. (PDD) and Simulations Plus Inc. (SLP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PDD and SLP operate in EDP Services (Technology), so they compete in similar markets.
- PDD is the larger of the two at $117.32B, about 313.5x SLP ($374.2M).
- Over the past year, PDD is down 37.0% and SLP is up 20.1% - SLP leads by 57.1 points.
- SLP has hit the wire 20 times in the past 4 weeks while PDD has been quiet.
- PDD has more recent analyst coverage (25 ratings vs 10 for SLP).
- Company
- PDD Holdings Inc.
- Simulations Plus Inc.
- Price
- $80.96-1.78%
- $18.50+0.00%
- Market cap
- $117.32B
- $374.2M
- 1M return
- +4.18%
- +0.41%
- 1Y return
- -36.98%
- +20.14%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 0
- 20
- Recent ratings
- 25
- 10
PDD Holdings Inc.
Pinduoduo Inc., through its subsidiaries, operates an e-commerce platform in the People's Republic of China. It operates Pinduoduo, a mobile platform that offers a range of products, including apparel, shoes, bags, mother and childcare products, food and beverage, fresh produce, electronic appliances, furniture and household goods, cosmetics and other personal care items, sports and fitness items, and auto accessories. The company was formerly known as Walnut Street Group Holding Limited and changed its name to Pinduoduo Inc. in July 2018. Pinduoduo Inc. was incorporated in 2015 and is headquartered in Shanghai, the People's Republic of China.
Simulations Plus Inc.
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Latest PDD
- PDD Holdings downgraded by Arete with a new price target
- Director Kam Anthony Ping Leung sold $140,151 worth of ADSs (1,705 units at $82.20), closing all direct ownership in the company (SEC Form 4)
- Director Kam Anthony Ping Leung converted options into 1,705 units of ADSs (SEC Form 4)
- SEC Form 6-K filed by PDD Holdings Inc.
- PDD Holdings Announces Second Quarter 2026 Unaudited Financial Results
- SEC Form 6-K filed by PDD Holdings Inc.
- PDD Holdings to Report Second Quarter 2026 Unaudited Financial Results on August 24, 2026
- Director Yeo George Yong-Boon converted options into 1,584 units of ADSs, increasing direct ownership by 6% to 27,212 units (SEC Form 4)
- SEC Form 4 filed by Co-Chief Executive Officer Zhao Jiazhen
- SEC Form 4 filed by SVP of Engineering Wang Mi
Latest SLP
- SEC Form 15-12G filed by Simulations Plus Inc.
- Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin
- SEC Form EFFECT filed by Simulations Plus Inc.
- SEC Form S-8 POS filed by Simulations Plus Inc.
- SEC Form S-8 POS filed by Simulations Plus Inc.
- SEC Form S-8 POS filed by Simulations Plus Inc.
- SEC Form S-8 POS filed by Simulations Plus Inc.
- SEC Form S-8 POS filed by Simulations Plus Inc.
- SEC Form POS AM filed by Simulations Plus Inc.
- SEC Form S-8 POS filed by Simulations Plus Inc.